News | Lung Imaging | September 21, 2020

Faster Lung Cancer Diagnosis, Treatment with Advanced 3-D Imaging Platform from Philips

Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room

Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room

September 21, 2020 — Philips introduced Azurion Lung Edition, an advanced 3-D imaging and navigation platform to accelerate the diagnosis and treatment of lung cancer. The suite combines CT-like 3-D images acquired at the tableside (Cone Beam CT) with live X-ray guidance and advanced tools to support image-guided lung procedures. The system is designed specifically for bronchoscopy procedures, enabling clinicians to perform both minimally invasive endobronchial biopsies and lesion ablation during the same procedure. By speeding diagnosis and treatment, Azurion Lung Edition is helping to transform lung cancer care, contributing to dramatically improved outcomes and reduced costs.

Each year 1.7 million people die worldwide of lung cancer, making it the leading cause of cancer deaths globally and accounting for more loss of life than breast, colon and prostate cancer combined. Today, over 60% of patients are diagnosed at a late stage, with a small chance of a surgical cure. But thanks to a rise in the number of lung cancer screening programs and increasing patient awareness, a growing proportion of patients have small peripheral lesions that are operable. 

In addition to early diagnosis, fast treatment is critical to ensure better outcomes and quality of life for lung cancer patients, with every week of delay resulting in a 5% increase in mortality. Today, most patients face a long journey to a definitive diagnosis and they often undergo a painful recovery after open surgery. Cone Beam CT is seen as the gold standard for clinicians to both diagnose and treat lung cancer in one room, and even during the same procedure.

“This is a very exciting time in the world of interventional pulmonology and advanced bronchoscopy,” said Michael Pritchett, M.D., pulmonary and critical care physician, Director, Chest Center of the Carolinas, FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, U.S. “One of the things that we’re particularly excited about is being able to diagnose patients, stage their cancer and treat them, all in a single procedure. As a diagnostic bronchoscopist it’s exciting and rewarding to be able not only to diagnose patients, but to go on to treat them as well.”

“Lung cancer is one of the most aggressive forms of cancer, and we need innovative technology to fight back,” said Gustavo Cumbo-Nacheli, M.D., Director of Bronchoscopy and Interventional Pulmonology at Spectrum Health in Grand Rapids, Michigan, U.S. “Without a Cone Beam CT scan to confirm placement of the biopsy needle, repeat procedures are often necessary. And by combining Cone Beam CT with other technologies, including robotics, we will be able to go beyond biopsy and treat the patient.”

On Wednesday, September 23 at 13:00 ET (19:00 CET). Atul Gupta, M.D., Interventional Radiologist and Chief Medical Officer, Philips Image Guided Therapy, will host an exclusive virtual roundtable together with a panel of renowned pulmonologists and interventional radiologists, “The Future Now: Implementing Cone Beam CT-guided endobronchial ablation therapy”. To register, click here.

“Image-guided minimally invasive procedures continue to expand into new treatment areas, enabled by sophisticated, procedure-oriented solutions like Azurion Lung Edition,” said Gupta. “With lung cancer increasingly being detected at an earlier stage, new minimally invasive treatment strategies like ablation have the potential to significantly improve outcomes for patients.” 

Intuitive, integrated and efficient, the Azurion platform optimizes clinical and operational lab performance and expands the role of image-guided interventions in the treatment of patients. The platform has achieved rapid global adoption and has been used in well over two million procedures worldwide. 

For more information: www.philips.com

Related Content

"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Ceiling-mounted X-ray system includes MyExam Companion intelligent user interface to guide technologist through exam workflow
News | X-Ray | October 26, 2020
October 26, 2020 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...